Halt Medical, Inc. Secures $92.8 Million Ahead Of U.S. Launch Of Uterine Fibroid Treatment

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Halt Medical has big plans for its Acessa System for treating uterine fibroids, having raised nearly $93 million in efforts to restructure debt and fund its commercial efforts.

California women's health company Halt Medical is raising capital ahead of a major commercial bid for its Acessa radiofrequency-based uterine fibroid treatment.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC